Jula Inrig's most recent trade in Travere Therapeutics Inc was a trade of 2,031 Common Stock done at an average price of $40.2 . Disclosure was reported to the exchange on Jan. 5, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Travere Therapeutics Inc | Jula Inrig | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 40.18 per share. | 05 Jan 2026 | 2,031 | 86,756 (0%) | 0% | 40.2 | 81,606 | Common Stock |
| Travere Therapeutics Inc | Jula Inrig | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 37.75 per share. | 05 Jan 2026 | 445 | 86,311 (0%) | 0% | 37.8 | 16,799 | Common Stock |
| Travere Therapeutics Inc | Jula Inrig | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Dec 2025 | 15,000 | 76,000 | - | - | Employee stock option (right to buy) | |
| Travere Therapeutics Inc | Jula Inrig | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 42.00 per share. | 24 Dec 2025 | 15,000 | 88,787 (0%) | 0% | 42.0 | 630,005 | Common Stock |
| Travere Therapeutics Inc | Jula Inrig | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.93 per share. | 24 Dec 2025 | 15,000 | 103,787 (0%) | 0% | 8.9 | 133,950 | Common Stock |
| Travere Therapeutics Inc | Jula Inrig | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 14.65 per share. | 01 Jul 2025 | 815 | 88,787 (0%) | 0% | 14.7 | 11,940 | Common Stock |
| Travere Therapeutics Inc | Jula Inrig | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2025 | 8,000 | 92,170 (0%) | 0% | - | Common Stock | |
| Travere Therapeutics Inc | Jula Inrig | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2025 | 8,000 | 0 | - | - | Performance-based restricted stock units | |
| Travere Therapeutics Inc | Jula Inrig | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 23.53 per share. | 10 Feb 2025 | 2,568 | 89,602 (0%) | 0% | 23.5 | 60,426 | Common Stock |
| Travere Therapeutics Inc | Jula Inrig | CHIEF MEDICAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 100,000 | 100,000 | - | - | Employee stock option (right to buy) | |
| Travere Therapeutics Inc | Jula Inrig | CHIEF MEDICAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 30,000 | 89,443 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Jula Inrig | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 20.12 per share. | 31 Jan 2025 | 4,207 | 85,236 (0%) | 0% | 20.1 | 84,645 | Common Stock |
| Travere Therapeutics Inc | Jula Inrig | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 20.11 per share. | 31 Jan 2025 | 1,066 | 84,170 (0%) | 0% | 20.1 | 21,437 | Common Stock |
| Travere Therapeutics Inc | Jula Inrig | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 19.10 per share. | 03 Jan 2025 | 2,066 | 59,883 (0%) | 0% | 19.1 | 39,461 | Common Stock |
| Travere Therapeutics Inc | Jula Inrig | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 18.76 per share. | 03 Jan 2025 | 440 | 59,443 (0%) | 0% | 18.8 | 8,254 | Common Stock |
| Travere Therapeutics Inc | Jula Inrig | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 12.98 per share. | 10 Sep 2024 | 684 | 61,949 (0%) | 0% | 13.0 | 8,878 | Common Stock |
| Travere Therapeutics Inc | Jula Inrig | CHIEF MEDICAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Sep 2024 | 6,750 | 64,824 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Jula Inrig | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 11.52 per share. | 05 Sep 2024 | 2,191 | 62,633 (0%) | 0% | 11.5 | 25,240 | Common Stock |
| Travere Therapeutics Inc | Jula Inrig | CHIEF MEDICAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 91,000 | 91,000 | - | - | Employee stock option (right to buy) | |
| Travere Therapeutics Inc | Jula Inrig | CHIEF MEDICAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 25,000 | 60,248 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Inrig Jula | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 8.53 per share. | 31 Jan 2024 | 2,174 | 58,074 (0%) | 0% | 8.5 | 18,547 | Common Stock |
| Travere Therapeutics Inc | Jula Inrig | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 9.48 per share. | 03 Jan 2024 | 2,069 | 35,688 (0%) | 0% | 9.5 | 19,613 | Common Stock |
| Travere Therapeutics Inc | Inrig Jula | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 9.17 per share. | 03 Jan 2024 | 440 | 35,248 (0%) | 0% | 9.2 | 4,035 | Common Stock |
| Travere Therapeutics Inc | Jula Inrig | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 54,500 | 54,500 | - | - | Employee stock option (right to buy) | |
| Travere Therapeutics Inc | Jula Inrig | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 20,250 | 37,757 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Jula Inrig | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 6,750 | 6,750 | - | - | Performance-based restricted stock units | |
| Travere Therapeutics Inc | Jula Inrig | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 20.75 per share. | 04 Jan 2023 | 2,051 | 17,949 (0%) | 0% | 20.7 | 42,558 | Common Stock |
| Travere Therapeutics Inc | Jula Inrig | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 20.75 per share. | 04 Jan 2023 | 442 | 17,507 (0%) | 0% | 20.8 | 9,172 | Common Stock |
| Travere Therapeutics Inc | Jula Inrig | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 8,000 | 8,000 | - | - | Performance-based restricted stock units | |
| Travere Therapeutics Inc | Jula Inrig | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2022 | 80,000 | 80,000 | - | - | Stock Option (Right to Buy) | |
| Travere Therapeutics Inc | Jula Inrig | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2022 | 20,000 | 20,000 (0%) | 0% | 0 | Common Stock |